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BACKGROUND Our study aimed to echocardiographically evaluate
myocardial adaption and outcome after transfemoral aortic valve
implantation (TAVI TF) for severe aortic stenosis based on LVEF.
METHODS From a total of 168 patients (pts.) who underwent TAVI TF
between 2010and2013 in our institution, n¼ 95with a follow-up-period3
months were included. Pts. were matched according to the Euro Score
(mean: 27.78 14.21%), anddivided into threegroups according tobaseline
left ventricular ejection fraction (LVEF; group 1: LVEF<40%,group2: LVEF
40%-55%, group3: LVEF>55%). LV functionwas assessedby conventional
and speckle-tracking based parameters. Mortality was registered up to 60
months (mean follow up period: 2917 months).
RESULTS Aortic valve oriﬁce and mean gradient signiﬁcantly
improved after TAVI in the whole collective in contrast to LV di-
mensions and LVEF, which largely remained unchanged (LV enddias-
tolic diameter: from 52.59.4 to 52.78.6mm; p¼0.59, LVEF from45.5
 10% to 47.8  13.9%, p¼0.13). However, pts. with reduced baseline
LVEF signiﬁcantly improved, while those with preserved LVEF
remained stable or slightly deteriorated (table 1). Changes of LVEF and
the global longitudinal strain (GLS) between group 1 and 3 were also
signiﬁcant (8.2  10.9% vs. -8.4  13.2%, p<0.0001 and -1.7  4.1% vs.
2.6  4.5%, p¼0.004 respectively). Kaplan Meier analysis revealed a
higher cumulative survival in patients with LVEF improvement as
compared to those with LVEF deterioration (p¼0.04, ﬁgure 1).Echocardiographic
parametersbaseline follow-upp-value
mean ± standard
deviation (median)mean ± standard
deviation (median)group1LVEF (Simpson, %) 29.98  8.31 (30) 39.47  12.28 (41) <0.001
GLS (%) -8.31  4.19 (-7.39) -9.01  3.69 (-3.94) 0.02
segmental strain
dispersion (msec)353.445  149.65
(353.50)315.49  118.13 (269) 0.04group 2LVEF (Simpson, %) 48.49  4.33 (49) 50.70  10.54 (48.22) 0.19
GLS (%) -12.12  4.50 (-12.02) -12.69  3.94 (-12.50) 0.28
segmental strain
dispersion (msec)271.85  120.10
(237.21)281.14  95.58 (275.19) 0.78group 3LVEF (Simpson, %) 65.19  7.02 (64) 56.59  13.17 (54.35) 0.004
GLS (%) -16.82  4.81 (-16.18) -14.59  5.12 (-14.08) 0.03
segmental strain
dispersion (msec)194.09  62.53
(185.01)230.70  123.99
(211.49)0.05CONCLUSIONS In patients with aortic stenosis and LVEF impairment
at baseline, TAVI results in an improved LVEF, while patients with a
high LVEF at baseline experience a normalization of LVEF after TAVI.
Independent of the baseline value, a deterioration of LVEF leads to a
signiﬁcant increase in mortality.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is a
treatment option for younger patients with symptomatic severe aortic
stenosis (AS) who seem to be high risk for surgical aortic valve
replacement due to signiﬁcant co-morbidities. However, very few
studies have investigated the feasibility and efﬁcacy of TAVI for
younger patients. Thus, the aim of this study is to evaluate the
feasibility and efﬁcacy of TAVI for younger patients.
METHODS Between October 2006 and October 2013, 790 consecutive
patients undergoing TAVI were included in the current analysis. The
cohort was divided into 2 groups: patients aged 75 years (n¼79) and
>75 years (n¼711).
RESULTS There were signiﬁcant differences with regard to major co-
morbidities which were more frequent in patients aged 75 years
compared to patients >75 years: history of cancer (22% vs 12%,
p<0.001), previous coronary artery bypass grafting (30% vs 11%,
p<0.001), and renal insufﬁciency requiring hemodialysis (11% vs 1%,
p¼0.007). With regard to echocardiography ﬁndings, ejection fraction
was signiﬁcantly lower in patients aged 75 years compared to pa-
tients >75 years (50.2% vs 54.4%, p¼0.016). With regard to outcomes,
there were no signiﬁcant differences in the procedural success rate
(92% vs 92%, p¼0.908), 30-day mortality (10% vs 11%, p¼0.747) and
30-day combined safety endpoint (21% vs 22%, p¼0.802) between the
2 groups. However, regarding mid-term outcome, the survival rate of
patients aged 75 years was signiﬁcantly higher in comparison with
patients aged >75 years (log-rank p¼0.037). The COX regression
model showed IDDM, life-threatening bleeding and creatinine clear-
ance (<60 ml/min) as the independent predictors of mid-term cu-
mulative mortality among younger patients.
CONCLUSIONS Although patients aged 75 years have more co-
morbidities compared to patients aged >75 years, TAVI can be effec-
tively and safely performed. Furthermore, mid-term outcome seems
to be better among the patients 75 years compared to patients aged
>75 years.
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BACKGROUND Based on data from the German Aortic Valve Registry
(GARY) a novel scoring system to predict 30-days or in hospital mor-
tality for either transvascular (tv) or transapical (ta) -TAVR was
developed.
METHODS 6249 pt undergoing tv-TAVR in 2011 and 2012 were
included in this ongoing non-randomized national multicenter regis-
try. In-hospital mortality or 30-days mortality (30dm) was chosen as a
binary outcome measure. First, 34 potential risk factors were tested in
an univariate manner by Fisher’s exact test for signiﬁcant inﬂuence on
mortality and multiple logistic regression with backward and forward
selection. Calibration was ascertained by the Hosmer-Lemeshow
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under the receiver operating characteristic (ROC) curve was
calculated. In 6249 of 6405 (97.6%) pts. survival status was known
and in 5413 (86.6%) pts a complete data set was available. The same
methods were then applied in 2317 ta-TAVR pts with a complete data
set.
RESULTS In tv-TAVR 30dm was 5.7%. Based on multiple logistic
regression, 15 risk factors impacting mortality were identiﬁed
including age, COPD, bicuspide aortic valve and others. The area un-
der the ROC curve with a value of 0.69 afﬁrmed the quality of
discrimination of the established scoring model. The model was then
tested prospectively on 3920 pts with full data set treated in the year
2013. Slightly less 30dm was observed than predicted in the very high
risk pts reﬂecting medical progress 2013 versus 2011/2012. In ta-TAVR
30dm was 8.5%, 13 risks factors partly different from transvascular pts
were identiﬁed and then prospectively tested. Some misalignment
between observed and predicted mortality could be demonstrated,
reﬂecting signiﬁcant inﬂuence of the ta-TAVR procedure outside pts
inherited risks.
CONCLUSIONS Based on GARY data the above models allows the
prediction of TAVR operative risks. Risk factors between tv- and ta-
TAVR deviate and risk prediction should be evaluated separately.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
TCT-674
Outcomes of Transfemoral Transcatheter Aortic Valve Implantation
Utilizing a Minimally Invasive Strategy
Ahmad Alkhalil,1 Guilherme F. Attizzani,2 Bimal Padaliya,3
Chor Cheung Tam,3 Hiram Bezerra,4 Basar Sareyyupoglu,5
Alan Markowitz,6 Daniel Simon,7 Marco Costa4
1Harrington Heart and Vascular Institute, University Hospitals Case
Medical Center, Clevleand, OH; 2Cardiovascular Imaging Core
Laboratory, Harrington Heart & Vascular Institute, University
Hospitals, Cleveland, OH; 3Harrington Heart and Vascular Institute,
University Hospitals Case Medical Center, Cleveland, OH; 4University
Hospitals Case Western School of Medicine, Cleveland, OH; 5Cardiac
Surgery, CWRU School of Medicine, Cleveland, OH; 6Cardiothoracic
surgery, CWRU School of Medicine, Cleveland, OH; 7Case Western
Reserve University School of Medicine, Cleveland, OH
BACKGROUND Transcatheter aortic valve implantation (TAVI) is
mainly done via a conventional strategy (CS); i.e., under general
anesthesia (GA) in hybrid operating rooms with transesophageal Echo
(TEE) guidance. Some centers, mostly in Europe, have demonstrated
the feasibility of a minimally invasive strategy (MIS); i.e., under local
anesthesia and conscious sedation without TEE guidance. Nonethe-
less, the experience of MIS for TAVI is largely limited in the United
States. Herein, we describe the evolution of an academic, high volume
TAVI program using either self- or balloon-expandable valves and its
transition from a CS to a MIS.
METHODS We, retrospectively, studied all transfemoral TAVI cases
with both commercially available self-expandable and balloon
expandable valves done at our institution between March 2011 and
November 2014. Patients were dichotomized according to the strategy
(MIS and CS). In-hospital, 30-day outcomes, gross cost data, and
midterm survival were evaluated.
RESULTS One hundred and sixteen patients were included in the MIS
group and 91 patients were included in the CS group. Baseline char-
acteristics were similar between groups. Procedural success was
comparable (99.1 % in MIS and 98.9 % in CS, p¼1). One intraprocedural
death occurred in each group. Conversion rate to GA was low (3.4%).
Length of hospital stay was signiﬁcantly reduced in the MIS (median
3.0 days [2.0,5.0]) compared to CS group (median 6.0 days [3.5,8.0]).
Complication rates were low and comparable between groups. Thirty-
day mortality and 30-day stroke/ transient ischemic attack rates were
similar (4.3% vs 4.4%; p¼1 and 0.9% vs 1.1%; p¼0.45, respectively). At
median follow up of 230 days, no signiﬁcant difference in survival was
detected (89 % vs. 88 %, p¼0.9). MIS was associated with cost saving
compared to CS (16000 $/case).
CONCLUSIONS This is the largest comparison between a MIS and a CS
for TAVI performed in the United States. TAVI via MIS was associated
with a shorter postprocedural hospital stay, lower hospital costs, and
similar safety proﬁle while keeping procedural efﬁcacy as compared to
CS.
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BACKGROUND New-onset conduction delays are one of the most
frequent complications after transcatheter aortic valve implantation
(TAVI). The purpose of this study was to evaluate the incidence of
new-onset intraventricular delays after TAVI with Edwards Sapien
aortic valves implantation.
METHODS A total of 136 consecutive patients undergoing TAVI with
Edwards Sapien aortic valves were included into a single-center
perspective registry between August 2011 and April 2015; 106 patients
received Edwards Sapien valves and 30 patients received Edwards Sapien
3 valves. Intraventricular conduction delays – deﬁned as right or left
bundle branch block – were assessed on ECGs acquired before TAVI,
immediately after TAVI, 24 hours after TAVI, and before discharge.
RESULTS The incidence of new-onset intraventricular conduction
delays was higher in patients treated with the Edwards Sapien 3 valve
as compared to those treated with the Edward Sapien valve (46.6% vs.
18.8%, P¼0.004). However, in 46% of patients treated with the
Edward Sapien 3 valve intraventricular conduction delays were tran-
sient, with complete resolution at discharge. No difference was
observed between patients treated with the Edwards Sapien 3 valve
and those treated the Edward Sapien valve in terms of deﬁnitive
pacemaker implantation after TAVI (10.7% vs 14.2%, P¼0-76).
CONCLUSIONS TAVI with new-generation Edwards Sapien 3 valve
might be associated with an increased risk of new-onset intraventricular
conduction delays. The latter, however, appears to be transient and not to
correlate with an increased risk of deﬁnitive pacemaker implantation.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS Conduction abnormalities, TAVI, Transcatheter aortic
valve replacement
TCT-676
Prognostic Impact of Neutrophil to Lymphocyte Ratio in Patients
Undergoing Transcatheter Aortic Valve Replacement
Yulanka Castro Dominguez,1 Atish P. Mathur,2 Daniel Angeli,2
Thomas Cocke,2 Pranaychandra Vaidya,2 Elie M. Elmann,2
Gabriele Di Luozzo,2 Arthur Ng,2 Elly Delaportas,2 Nierenberg Hillary,2
Joseph Parrillo2
1Rutgers - New Jersey Medical School, Newark, NJ; 2Hackensack
University Medical Center, Hackensack, NJ
BACKGROUND Previous studies have demonstrated that a high neutro-
phil to lymphocyte ratio (NLR) is amarker of inﬂammation andprogression
of atherosclerosis. NLR has also been shown to be signiﬁcantly elevated in
patientswith severe calciﬁc aortic stenosis.However, prognostic relevance
of highNLR in patients undergoingTranscatheter aortic valve replacement
(TAVR) on operative mortality is not clearly deﬁned.
METHODS We retrospectively evaluated 166 consecutive patients
undergoing TAVR at our institution between 2012 and 2014. Baseline
characteristics, 30 day major adverse cardiovascular events (MACE),
deﬁned as composite end point of stroke, myocardial infarction, car-
diovascular death or re-hospitalization, and 30 day all-cause mortality
were analyzed. NLR was calculated as ratio of absolute neutrophil
count to absolute lymphocyte count, prior to TAVR procedure.
RESULTS The mean ( SD) total white blood cell, absolute neutrophil
and lymphocyte counts were 6.8 ( 1.8) x 103/mL, 4.6 (1.6) x 103/mL and
1.2 (0.5) x 103/mL, respectively. The mean ( SD) NLR was 4.5 ( 2.5).
NLR was signiﬁcantly correlated with pulmonary artery systolic pressure
(r ¼ 0.23, p ¼ 0.008) and society of thoracic society (STS) score (r ¼ 0.21,
p ¼ 0.02). ). On multivariate cox regression survival analysis, after
adjusting for age, gender, ethnicity, STS score, left ventricular ejection
fraction, pulmonary artery systolic pressure, history of diabetes mellitus,
peripheral vascular and cerebrovascular disease, patients with a NLR > 4
had signiﬁcantly reduced survival at 30 days when compared to those
with NLR < 4 (83.6% vs. 95.6%, hazard ratio (HR) 4.23, 95% conﬁdence
interval (CI): 1.04 to 17.26, p ¼ 0.04).
